Cellworks

About Cellworks

Cellworks Group is a life sciences technology company specializing in personalized medicine for oncology and immunology. The company has developed a biosimulation platform that uses a patient's genomic data to create a personalized disease model. This model can then be used to test the efficacy of various FDA-approved cancer therapies and predict a patient's response to them.

The core of Cellworks' offering is its Computational Biology Model, which simulates how a patient's biological system will interact with different treatments. This allows for the creation of personalized therapy recommendations, aiming to improve patient outcomes. The company's services are delivered through reports, such as the SINGULA TM Standard Care Response report, which provides insights into a patient's likely response to standard cancer treatments.

Cellworks operates on a B2B model, likely serving oncology clinics, hospitals, and pharmaceutical companies. For clinical partners, the platform aids in making personalized therapy decisions for individual patients. For pharmaceutical clients, the technology can be used in precision drug development to identify patient cohorts most likely to respond to a new drug. The company generates revenue through its personalized medicine products and biosimulation services.